Fundraising Fox
/Companies
Sign in

Cytovation

Bergen, NO · Founded 2015 · 13 employees on LinkedIn · 2 known investors

Find your way into Cytovation

Sign up to see every warm intro you have to Cytovation

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Cytovation team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Cytovation develops immunotherapy treatments designed to enhance immune response against various cancer types, with a focus on engineered synthetic peptides and first-in-class therapeutic candidates. The company is built on research foundations from Norwegian academic institutions and serves oncology and immunology markets.

BiotechHealthtechMedical Devices

Founders & leadership

Cytovation was founded in 2015 by Lars Prestegarden.

LPLars Prestegarden
Lars PrestegardenCo-founder & Chief Executive Officer (CEO)

Investors · 2

CanicareportedOslo

How we know: globenewswire.com · Not right? Tell us

Funding

SEC filings, press & company announcements

$14M disclosed across 2 rounds · 2023–2025

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readoutsglobenewswire.com · Apr 2025Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts - Cytovation AScytovation.com · Apr 2025Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapyglobenewswire.com · Jun 2023

Frequently asked questions

What does Cytovation do?
Cytovation develops immunotherapy treatments designed to enhance immune response against various cancer types, with a focus on engineered synthetic peptides and first-in-class therapeutic candidates. The company is built on research foundations from Norwegian academic institutions and serves oncology and immunology markets.
Who founded Cytovation?
Cytovation was founded by Lars Prestegarden in 2015.
Who are Cytovation's investors?
Cytovation's investors include Sandwater, Canica.
How much funding has Cytovation raised?
Cytovation has disclosed $14M raised across 2 rounds.
Where is Cytovation headquartered?
Cytovation is headquartered in Bergen, NO.